NOVARTIS AG NAMENS-AKTIEN SF 0,5
NOVARTIS AG NAMENS-AKTIEN SF 0,5/ CH0012005267 /
904278
07.09.2024 13:04:24
|
Zm.
-0,100
|
Wolumen |
Bid13:04:24 |
Ask13:04:24 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
104,440EUR
|
-0,10%
|
- Obrót: - |
104,440Wolumen Bid: - |
105,860Wolumen Ask: - |
240,16 mldEUR |
- |
- |
Opis działalności
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
Zarząd & Rada nadzorcza
CEO |
Vasant Narasimhan, M.D. |
Zarząd |
Harry Kirsch, Dr. Klaus Moosmayer, Dr. Steffen Lang, Karen L. Hale, Rob Kowalski, Shreeram Aradhye, Victor Bulto, Aharon (Ronny) Gal, Dr. Fiona H. Marshall, Patrick Horber |
Rada nadzorcza |
Dr. Joerg Reinhardt, Bridgette Heller, Charles L. Sawyers, M.D., Dr. Charlotte Pamer-Wieser, Dr. Nancy C. Andrews, Elizabeth Doherty, Frans van Houten, Simon Moroney, Ton Buechner, William T. Winters, Daniel Hochstrasser, Ana de Pro Gonzalo, John D. Young, Patrice Bula |
Dane firmy
Nazwa: |
Novartis AG |
Adres: |
Lichtstrasse 35,CH-4002 Basel |
Telefon: |
+41-61-324-1111 |
Fax: |
+41-61-324-8001 |
E-mail: |
-
|
Internet: |
www.novartis.com |
Przemysł: |
Służba zdrowia |
Sektor: |
Przemysł Farmaceutyczny |
Podsektor: |
Przemysł Farmaceutyczny |
Koniec roku finansowego: |
31.12 |
Free float: |
86,85% |
Data IPO: |
07.03.1996 |
Główni akcjonariusze
Inne |
|
54,16% |
Morgan Stanley |
|
32,00% |
Novartis AG |
|
7,18% |
Sandoz Family Foundation |
|
3,71% |
Dodge & Cox Inc |
|
0,72% |
Primecap Management Company |
|
0,66% |
Loomis Sayles & Company, LP |
|
0,28% |
Franklin Resources, Inc. |
|
0,27% |
Dimensional Fund Advisors LP |
|
0,27% |
Inne |
|
0,75% |